Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Jean-Blaise Eckert | M | 61 |
Xigen SA
 Xigen SA Pharmaceuticals: MajorHealth Technology Xigen SA develops intracellular peptide therapeutics for the treatment of stroke, myocardial infarction and cancer. It focuses on the acute or short-term treatment of major debilitating pathologies that underly unmet medical needs plaguing humanity. The company was founded in 2002 and is headquartered in Epalinges, Switzerland. | - |
| Pascal Nicod | M | - |
Xigen SA
Xigen SA Pharmaceuticals: MajorHealth Technology Xigen SA develops intracellular peptide therapeutics for the treatment of stroke, myocardial infarction and cancer. It focuses on the acute or short-term treatment of major debilitating pathologies that underly unmet medical needs plaguing humanity. The company was founded in 2002 and is headquartered in Epalinges, Switzerland. | - |
| Samuel Wickline | M | 71 | 3 anni | |
| Marc Mathieu | M | - |
Xigen SA
Xigen SA Pharmaceuticals: MajorHealth Technology Xigen SA develops intracellular peptide therapeutics for the treatment of stroke, myocardial infarction and cancer. It focuses on the acute or short-term treatment of major debilitating pathologies that underly unmet medical needs plaguing humanity. The company was founded in 2002 and is headquartered in Epalinges, Switzerland. | - |
| Dennis J. Church | M | - |
Xigen SA
Xigen SA Pharmaceuticals: MajorHealth Technology Xigen SA develops intracellular peptide therapeutics for the treatment of stroke, myocardial infarction and cancer. It focuses on the acute or short-term treatment of major debilitating pathologies that underly unmet medical needs plaguing humanity. The company was founded in 2002 and is headquartered in Epalinges, Switzerland. | - |
| Géraldine Dury | M | - |
Xigen SA
Xigen SA Pharmaceuticals: MajorHealth Technology Xigen SA develops intracellular peptide therapeutics for the treatment of stroke, myocardial infarction and cancer. It focuses on the acute or short-term treatment of major debilitating pathologies that underly unmet medical needs plaguing humanity. The company was founded in 2002 and is headquartered in Epalinges, Switzerland. | - |
| Thomas Meyer | M | 56 |
Zilentin AG
 Zilentin AG Pharmaceuticals: MajorHealth Technology Zilentin AG develops projects for the treatment of tinnitus and hearing loss. The company is headquartered in Zug, Switzerland. | - |
| Sazonov Mikhail | M | - |
Xigen SA
Xigen SA Pharmaceuticals: MajorHealth Technology Xigen SA develops intracellular peptide therapeutics for the treatment of stroke, myocardial infarction and cancer. It focuses on the acute or short-term treatment of major debilitating pathologies that underly unmet medical needs plaguing humanity. The company was founded in 2002 and is headquartered in Epalinges, Switzerland. | - |
| Marcel Gremaud | M | 66 | 3 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Raoul F. Dias | M | - | - | |
| Margrit Schwarz | M | 60 | 3 anni | |
| Andrea Vondraskova | M | - | - |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Svizzera | 7 | 58.33% |
| Bermuda | 5 | 41.67% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Elmar Schärli
- Contatti personali
